GLP-1 medications are best known for weight management and blood sugar control. Now dermatologists and researchers are asking a new question: could they also help chronic inflammatory skin conditions? Early research is promising, but it is early. Here is what is known about GLP-1s, psoriasis, and hidradenitis suppurativa, and what it means for you.
Why are researchers looking at GLP-1s for skin conditions?
Psoriasis and hidradenitis suppurativa (HS) are chronic inflammatory conditions, and both are closely linked to excess weight and metabolic health. Obesity can make them more likely, more severe, and harder to treat. Fat tissue releases inflammatory signals, and insulin resistance can add to the problem.
GLP-1 receptor agonists such as semaglutide and tirzepatide help with weight loss, blood sugar, and inflammation. That combination is why researchers are interested. Human skin also has GLP-1 receptors, especially when it is inflamed, which raises the question of whether the medication has direct effects on the skin as well. That idea is still being studied.
What does the research show for psoriasis?
Weight loss is already known to help psoriasis. In people with overweight or obesity, losing weight can reduce psoriasis severity and may help other treatments work better.
Studies of GLP-1s specifically are smaller. Some analyses of liraglutide, an older GLP-1, found improvement in psoriasis severity scores, and small studies reported better skin inflammation and quality of life over about 12 weeks. Other studies have not found a clear benefit, particularly in people with obesity who do not have diabetes. Larger trials combining tirzepatide with a psoriasis biologic are underway. Until they report, it is not clear how much of the benefit comes from the medication itself and how much from weight and blood sugar improvements.
What does the research show for hidradenitis suppurativa?
HS causes painful lumps, abscesses, and scarring, often in skin folds. Weight loss is associated with fewer flares and less severe disease. Case reports and small studies have described improvement in HS symptoms and quality of life with semaglutide and liraglutide, likely from both metabolic and anti-inflammatory effects. The evidence is limited to small studies, so it is too early to call GLP-1s a standard treatment.
What about wound healing?
Animal studies suggest GLP-1s may help wound healing by encouraging new blood vessel growth and skin cell migration. This has not been shown in people, and it should not be a reason to start a GLP-1.
Who might benefit?
The strongest case is for people who have a chronic skin condition and also have obesity or type 2 diabetes. For them, a GLP-1 may help the skin and the metabolic health at the same time. In lean people, benefit for skin conditions is unproven.
What are the skin-related side effects of GLP-1s?
GLP-1s can also affect the skin. Reported effects include injection-site reactions, rashes, and unusual skin sensations such as burning or tingling. Rapid weight loss can also cause hair shedding and changes in facial fullness. Tell your provider about any new skin symptoms.
What should you do if you have a chronic skin condition?
- Do not stop your current treatment. GLP-1s are not approved for psoriasis or HS and are not a replacement for treatment from your dermatologist.
- Tell your dermatologist and your GLP-1 provider about each other. Care works best when your providers coordinate.
- Ask about your health markers. Weight, blood sugar, and cholesterol all matter for inflammatory skin disease.
- Report changes. Let your providers know if your skin gets better, worse, or different after you start.
DrWell and GLP-1 therapy
DrWell providers prescribe GLP-1 therapy for weight management and metabolic health after reviewing your history and goals. GLP-1s are not FDA approved to treat psoriasis, HS, or other skin conditions. Compounded medications are not FDA approved, and treatment is personalized.
%20(1)%20(1)%20(1).png)